CovidSurg-Cancer (GO) is a global observational cohort study looking at the impact of COVID-19 on the care of patients with gynaecological malignancies requiring surgery

Background and aim

The rapid emergence of the Coronavirus disease 2019 (COVID-19) across the world has forced the redesign of clinical services to make difficult decisions regarding cancer surgery. During this pandemic, surgical treatments can put cancer patients at higher risk of post-operative complications, but delay in treatments can lead to poorer outcomes. There is an urgent need to better understand the impact of COVID-19 on care of cancer patients requiring surgery. CovidSurg-Cancer (GO) aims to assess the outcomes of gynaecological cancer patients with decision for surgery.

Eligible hospitals/centers: Any hospitals/centers performing elective gynaecological cancer surgery.

Inclusion criteria:

- Patients who are undergoing surgery for gynaecological cancers with curative intent or life-prolonging intent during the COVID-19 pandemic.
- Patients with gynaecological cancers that would have been planned for curative or life-prolonging cancer surgery in the pre-COVID-era, who have surgery delayed or cancelled during the COVID-19 pandemic.
- Patients who are undergoing surgery for gynaecological cancers with curative intent or life-prolonging intent during the COVID-19 pandemic with/who develop COVID-19.

Key study outcomes:

- Primary: 30-day postoperative COVID-19 infection rate
- Secondary: 30-day postoperative mortality and critical care admission; delay in surgery >4 weeks; progression to inoperable or incurable disease at 3 months,

Data collection period: 3 months from the time of emergence of COVID-19 in the enrolled hospitals (as identified by local investigators). Both retrospective and prospective data collection are permissible.

Follow up: 3 months from the time of study entry (when care decision was made) for each participant.

Data storage: Anonymised data will be collected and stored in a secure online platform (REDCap).

Authorship: All the collaborators will be recognised as co-authors in any publications resulting from this study. A corporate authorship model will be used under CovidSurg Collaborative group, for example: https://pubmed.ncbi.nlm.nih.gov/29452941

Email for CovidSurg-Gynaecological Oncology: gocovidsurg@gmail.com

Website for CovidSurg-Cancer: https://globalsurg.org/cancercovidsurg

[Version 2] 20 April 2020